Theriva Biologics Addresses NYSE Trading Volatility While Advancing Oncology Pipeline

Market Activity Clarification

On October 24, 2025, Theriva Biologics, Inc. (NYSE American: TOVX) disclosed that unusual trading volume had been detected in its common stock. Following standard regulatory procedures outlined in NYSE Company Guide Section 401(d), the company conducted a thorough internal review. The investigation revealed no material business developments or undisclosed events that would explain the trading pattern. The company determined that no corrective measures were warranted at this time.

Clinical Progress Provides Context

The timing of the market activity coincided with recent clinical developments. Just 11 days prior, on October 13, 2025, Theriva Biologics had presented expanded data from its VIRAGE trial at the European Society for Medical Oncology (ESMO 2025) Annual Congress. The trial focused on VCN-01 (zabilugene almadenorepvec), the company’s lead therapeutic candidate, with findings shared during a mini oral session at the prestigious European oncology forum.

Understanding Theriva Biologics’ Approach

Theriva Biologics operates as a diversified clinical-stage biotechnology company focused on developing novel cancer treatments addressing significant medical gaps. The company’s subsidiary, Theriva Biologics, S.L., has pioneered an oncolytic adenovirus platform designed for multiple delivery routes—intravenous, intravitreal, and direct tumor administration—to achieve three therapeutic objectives: triggering selective tumor cell death, breaking down stromal barriers that impede cancer drug penetration, and activating robust immune system responses against remaining cancer cells.

Lead Product Candidates in Development

The company’s primary pipeline consists of three distinct therapeutic programs:

VCN-01 represents the most advanced candidate in the oncology portfolio. As an engineered oncolytic adenovirus, it selectively replicates within tumor tissues while degrading the protective stroma that typically shields tumors from treatment and immune attack. This dual mechanism aims to enhance both direct cytotoxicity and the effectiveness of concurrent therapies.

SYN-004 (ribaxamase) addresses a different therapeutic challenge in the transplant setting. The enzyme is designed to degrade specific intravenous beta-lactam antibiotics within the gastrointestinal tract, preserving the patient’s beneficial microbiome flora. By preventing pathogenic overgrowth—particularly vancomycin-resistant Enterococci (VRE)—the approach seeks to reduce both the incidence and severity of acute graft-versus-host-disease (aGVHD) in patients receiving allogeneic hematopoietic cell transplants (HCT).

SYN-020 takes an oral formulation approach using intestinal alkaline phosphatase (IAP). Manufactured under stringent cGMP standards, this recombinant enzyme candidate is positioned to treat both localized gastrointestinal and systemic disease states, broadening Theriva Biologics’ therapeutic reach beyond oncology.

For additional company information and investor updates, stakeholders can access Theriva Biologics’ resources at www.therivabio.com.